AIM ImmunoTech Inc.: AIM ImmunoTech Provides Summary of Ampl

Ampligen has demonstrated in pre-clinical and now human clinical studies a potential to enhance efficacy of PD-1 and/or PD-L1 checkpoint inhibitors Ampligen's anti-tumor potential is demonstrated with

Related Keywords

United States , American , Pawel Kalinski , Jenene Thomas , Michael Tony Hollingsworth , Roswell Park , Robert Edwards , Bob Edwards , Cancersshowing Ampligen , Thomas Equels , Roswell Park Comprehensive Cancer Center , Immunotech Inc , University Of Nebraska Medical Center , University Of Pittsburgh Medical Center , University Of Pittsburgh School Medicine , University Of Pittsburgh Cancer Institute , Buffett Cancer Center , Division Of Translational Immuno , Steam Science , Chief Executive Officer , Associate Director , Basic Research , Nebraska Medical , Pittsburgh School , Pittsburgh Cancer , Jacobs Family Endowed Chair , Translational Immuno Oncology , Senior Vice President , Roswell Park Comprehensive Cancer , Ovarian Cancer , Pittsburgh Medical Center , Triple Negative Breast Cancer , Private Securities Litigation Reform Act , Immunotech , Rovides , Summary , Ampligen , Data , Supporting , Synergistic , Potential , Checkpoint , Blockade , Therapies ,